NasdaqGS - Nasdaq Real Time Price USD

Inozyme Pharma, Inc. (INZY)

4.3900

-0.1200

(-2.66%)

At close: April 22 at 4:00 PM EDT

4.4696

+0.08

(+1.81%)

After hours: April 22 at 6:59 PM EDT

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) - - Natural history study highlights stroke as common feature among patients with early-onset ABCC6 Deficiency - - Favorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing in ongoing and future clinical trials - -

GlobeNewswire 14 days ago

INZY
-2.66%
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it granted stock options to three new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, as inducement material to the new employees entering

GlobeNewswire 17 days ago

INZY
-2.66%
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Doug Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 from 10

GlobeNewswire 20 days ago

INZY
-2.66%
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m. Eastern Ti

GlobeNewswire 27 days ago

INZY
-2.66%
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April – – Phase 1 trial of INZ-701 in end-stage kidney disease (ESKD) patients receiving hemodialysis (SEAPORT-1) now underway (NCT06283589), with topline data expected in Q4 2024 – – Launched global patient registry (PROPEL) in partnership with GACI Global to advance understanding of ENPP1 Deficiency and infantile-onset ABCC6 Deficiency (NCT06302439) – – Cash, cash equi

GlobeNewswire last month

INZY
-2.66%
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -BOSTON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate in an Orphan Bone & Neuromuscula

GlobeNewswire last month

INZY
-2.66%
Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

Key Insights Given the large stake in the stock by institutions, Inozyme Pharma's stock price might be vulnerable to...

Simply Wall St. 3 months ago

INZY
-2.66%
Inozyme Pharma to Participate in Upcoming Investor Conferences

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company’s chief executive officer and chairman of the board, will participate at the following investor conferences: The Jefferies London Healthcare Conference. The presentation will

GlobeNewswire 5 months ago

INZY
-2.66%
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in first quarter of 2024 – – Cash, cash equivalents, and short-term investments as of September 30, 2023 expected to fund operations into the fourth quarter of 2025 – BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, In

GlobeNewswire 5 months ago

INZY
-2.66%
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held November 2-5, 2023 in Philadelphia, PA. Details of the presentation are as follows: Title: Role of Plasma Inorgan

GlobeNewswire 5 months ago

INZY
-2.66%
10 Stocks With Huge Catalysts on the Way

In this article, we will take a look at the 10 stocks with huge catalysts on the way. To see more such companies, go directly to 5 Stocks With Huge Catalysts on the Way. The US stock market continues to be in a see-saw mode as investors gauge and digest latest data. The latest jobs […]

Insider Monkey 6 months ago

CMG

GOLF

INZY
-2.66%
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 6 months ago

INZY
-2.66%
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, highlighted the inclusion of Generalized Arterial Calcification of Infancy (GACI), which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic England’s Generation Study. This research initiative, embedded within the UK

GlobeNewswire 6 months ago

INZY
-2.66%
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting, which is being held October 13-16, 2023 in Vancouver, BC, Canada. Details of the presentations are

GlobeNewswire 6 months ago

INZY
-2.66%
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) trial - - INZ-701 was generally well tolerated and exhibited a favorable safety and immunogenicity profile in both trials - - Company to host conference call and webcast today at 8:00 a.m. ET - BOSTON, Sept. 26,

GlobeNewswire 6 months ago

INZY
-2.66%
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Company to share interim data updates from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host an Investor and Analyst Event on Tuesday, September 26, 2023

GlobeNewswire 6 months ago

INZY
-2.66%
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET. A live webcast of the p

GlobeNewswire 7 months ago

INZY
-2.66%
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to serve as primary endpoint in the U.S. and co-primary endpoint in the EU for ENERGY-3 pediatric pivotal trial for ENPP1 Deficiency; initiation expected in October 2023 – – Cash, cash equivalents, and short-term investments as of June 30, 2023, together with proceeds from July 2023 offering, expected to fund cash flow req

GlobeNewswire 8 months ago

INZY
-2.66%
Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)

Investors are constantly looking for different ways to beat the market and there are several routes to follow in that pursuit. One common strategy is to keep track of the insiders’ moves. By insiders, we mean the corporate officers responsible for their own companies’ performance, who also naturally know the inner workings of the firms they work for better than anyone else. When they are seen picking up shares of company stock – by law they are required to make the transactions public – it sends

TipRanks 8 months ago

HRTX

INZY
-2.66%
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced the closing of its underwritten public offering of 14,375,000 shares of its common stock at a price of $4.80 per share. The shares of common stock issued and sold in the public offering at the closing include 1,875,000 shares issued upon the exe

GlobeNewswire 8 months ago

INZY
-2.66%

Performance Overview

Return	INZY	S&P 500
YTD	+3.05%	+5.05%
1-Year	-28.73%	+21.22%
3-Year	-76.62%	+20.06%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inozyme Pharma, Inc. (INZY)

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights

Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference

Institutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)

Inozyme Pharma to Participate in Upcoming Investor Conferences

Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023

10 Stocks With Huge Catalysts on the Way

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions

Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting

Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)

Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Insiders Pour Millions Into These 2 Stocks Under $10 — Here’s Why Wall Street Thinks They Could Double (or More)

Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock

Performance Overview